Scotiabank Analyst Sees Opportunity in Large Cap Biopharma, Keeps Outperform on GILD

Group 1: Company Overview - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as one of the 15 Best Passive Income Stocks to Buy Right Now [1] - Gilead remains a reliable dividend payer, with shares increasing over 36% since the beginning of 2025, outperforming the broader market [3] Group 2: Financial Performance - In the third quarter, Gilead reported total revenue of $7.8 billion, reflecting a 3% increase year-over-year [3] - Oncology revenue experienced a decline of 3% year-over-year, totaling $788 million in the third quarter [4] Group 3: Market Position and Future Outlook - Gilead continues to lead the HIV drug market, which is a significant driver of its growth [3] - The company has a large and active oncology pipeline, now larger than its HIV portfolio, with expectations for label expansions and new approvals in the cancer market to boost overall sales in the coming years [4] - Scotiabank analyst Louise Chen maintains an Outperform rating on Gilead, highlighting the potential for attractive entry points in large-cap biopharma stocks before the next wave of innovation [2]